Genscript Biotech has expanded peptide production capabilities at its new life sciences manufacturing facility located in Zhenjiang, China, to include neoantigen peptide and peptide active pharmaceutical ingredients (API).
The expansion aims to meet the urgent demands of GenScript’s global biotech customers for the delivery of new drugs to market.
GenScript associate marketing director Raymond Miller stated: “As a leader in peptide synthesis, we recognise the growing market need for fast-track production of cGMP-grade peptides.
“With an increasing number of peptide drugs moving from drug discovery to clinical trials and commercialisation, it is critical that we meet the urgent demands of our customers.
“With over 20 years of experience in peptide synthesis, it is a natural progression for us to enter the cGMP peptide market and support increasing market demands.”
GenScript will use its extensive manufacturing expertise to synthesise these complex and modified peptides.
The cGMP manufacturing facility will deliver up to 48 personalised neoantigen sequences per patient per batch, and 500 items of sterile product per month.
It can also deliver orders of up to 800g peptide APIs per month (more than 20kg per year).
GenScript regulatory affairs director Hui Feng stated: “GenScript’s capabilities go way beyond peptide manufacturing — our professional regulatory affairs team provides extensive support in CMC [chemistry, manufacturing and controls] filing documents and the development of global regulatory strategies for peptide new drugs, including drug substances, and drug products.
“We take on your challenges as if they were our own, and we’re committed to delivering high-quality peptides on time, every time.”
